MA55799A - Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2 - Google Patents

Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2

Info

Publication number
MA55799A
MA55799A MA055799A MA55799A MA55799A MA 55799 A MA55799 A MA 55799A MA 055799 A MA055799 A MA 055799A MA 55799 A MA55799 A MA 55799A MA 55799 A MA55799 A MA 55799A
Authority
MA
Morocco
Prior art keywords
aprmilast
combination therapies
therapies including
tyk2 inhibitors
tyk2
Prior art date
Application number
MA055799A
Other languages
English (en)
Inventor
Mary Adams
Lisa Beebe
Gilles Buchwalter
Tiffany Carr
Robert Plenge
Peter Henry Schafer
Te-Chen Tzeng
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MA55799A publication Critical patent/MA55799A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
MA055799A 2019-04-30 2020-04-30 Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2 MA55799A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/029772 WO2020222773A1 (fr) 2019-04-30 2019-04-30 Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2

Publications (1)

Publication Number Publication Date
MA55799A true MA55799A (fr) 2022-03-09

Family

ID=66476870

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055799A MA55799A (fr) 2019-04-30 2020-04-30 Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2

Country Status (14)

Country Link
EP (2) EP3962475A1 (fr)
JP (2) JP2022537877A (fr)
KR (2) KR20220002488A (fr)
CN (3) CN114269336A (fr)
AU (2) AU2019443366A1 (fr)
BR (2) BR112021021809A2 (fr)
CA (2) CA3138473A1 (fr)
CL (1) CL2021002847A1 (fr)
CO (2) CO2021015622A2 (fr)
IL (2) IL287665A (fr)
MA (1) MA55799A (fr)
MX (2) MX2021013317A (fr)
SG (2) SG11202112043PA (fr)
WO (2) WO2020222773A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114269336A (zh) * 2019-04-30 2022-04-01 细胞基因公司 包含阿普斯特和tyk2抑制剂的联合疗法
JP2024508794A (ja) 2021-02-19 2024-02-28 スドー バイオサイエンシーズ リミテッド Ｔｙｋ２阻害剤およびその使用
CA3207819A1 (fr) 2021-02-19 2022-08-25 Anjali Pandey Inhibiteurs de tyk2 et leurs utilisations
JP2024507253A (ja) 2021-02-19 2024-02-16 スドー バイオサイエンシーズ リミテッド Ｔｙｋ２阻害剤およびその使用
EP4335440A4 (fr) * 2021-05-04 2025-05-14 Shanghai Zheye Biotechnology Co., Ltd. Composé de pyridine hétérocyclique contenant de l'azote
CN118251222A (zh) * 2021-09-23 2024-06-25 百时美施贵宝公司 用tyk2抑制剂治疗脱发障碍的方法
EP4423086A1 (fr) 2021-10-25 2024-09-04 Kymera Therapeutics, Inc. Agents de dégradation de tyk2 et leurs utilisations

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
US8367689B2 (en) * 2009-05-06 2013-02-05 Portola Pharmaceuticals, Inc. Inhibitors of JAK
EP2638018A1 (fr) 2010-11-09 2013-09-18 Cellzome Limited Composés de pyridine et leurs analogues aza en tant qu'inhibiteurs de tyk2
ES2661583T3 (es) * 2011-04-28 2018-04-02 Celgene Corporation Métodos y composiciones usando inhibidores de PDE4 para el tratamiento y gestión de enfermedades autoinmunes e inflamatorias
HUE050327T2 (hu) 2011-12-27 2020-11-30 Amgen Europe Gmbh Készítmények (+)-2-[1-(3-etoxi-4-metoxifenil)-2-metánszulfonil-etil]-4-acetilaminoizoindolin-1,3-dion tartalommal
KR20140108594A (ko) 2012-01-10 2014-09-11 에프. 호프만-라 로슈 아게 피리다진 아미드 화합물 및 syk 저해제로서의 이의 용도
EP2832734A4 (fr) 2012-03-28 2015-08-26 Takeda Pharmaceutical Composé hétérocyclique
US9296725B2 (en) 2012-05-24 2016-03-29 Cellzome Limited Heterocyclyl pyrimidine analogues as TYK2 inhibitors
AU2013341186B2 (en) * 2012-11-08 2017-03-30 Bristol-Myers Squibb Company Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
CA2890935A1 (fr) * 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Composes de pyrimidine a substitution d'amide alkyl utiles pour la modulation des il-12, il 23 et ifn.alpha
NZ628320A (en) * 2013-03-14 2017-04-28 Celgene Corp Treatment of psoriatic arthritis using apremilast
EP3029031A4 (fr) 2013-07-30 2017-01-11 Takeda Pharmaceutical Company Limited Composé hétérocyclique
CN105793245B (zh) 2013-09-03 2018-03-20 萨勒姆有限公司 药物化合物
AR094537A1 (es) 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
EP3080131B1 (fr) 2013-12-10 2018-10-10 Bristol-Myers Squibb Company Composés imidazopyridazines utiles en tant que modulateurs de réponses à il-12, il-23 et/ou ifn-alpha
WO2015091584A1 (fr) 2013-12-18 2015-06-25 F. Hoffmann-La Roche Ag Composés de thiazolopyridine, compositions et leur utilisation comme inhibiteurs de la kinase tyk2
US9834548B2 (en) * 2014-02-14 2017-12-05 Portola Pharmaceuticals, Inc. Pyridazine compounds as JAK inhibitors
EP4019518A1 (fr) 2014-02-28 2022-06-29 Nimbus Lakshmi, Inc. Inhibiteurs de tyk2 et utilisations associées
JP6687550B2 (ja) 2014-06-23 2020-04-22 セルジーン コーポレイション 肝疾患又は肝機能異常を治療するためのアプレミラスト
US10092541B2 (en) * 2014-08-15 2018-10-09 Celgene Corporation Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast
NO2721710T3 (fr) 2014-08-21 2018-03-31
WO2016047678A1 (fr) 2014-09-25 2016-03-31 武田薬品工業株式会社 Composé hétérocyclique
ES2930585T3 (es) 2015-02-27 2022-12-19 Nimbus Lakshmi Inc Inhibidores de TYK2 y usos de los mismos
JP6802263B2 (ja) 2015-09-02 2020-12-16 ニンバス ラクシュミ， インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
ES2794779T3 (es) 2016-02-24 2020-11-19 Pfizer Derivados de pirazolo[1,5-a]pirazin-4-ilo como inhibidores de JAK
KR102531036B1 (ko) 2016-10-07 2023-05-09 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물
CN115448916B (zh) 2016-10-14 2026-04-28 武田药品工业株式会社 Tyk2抑制剂及其用途
JP7082120B2 (ja) 2016-10-21 2022-06-07 ニンバス ラクシュミ， インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
KR102477063B1 (ko) 2016-10-28 2022-12-12 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 헤테로비시클릭 화합물
US11299494B2 (en) 2016-11-17 2022-04-12 Bristol-Myers Squibb Company Substituted imidazo[1,2-b]pyridazines as interleukin-23 and interferon-α modulators
GB2562702B (en) 2017-03-06 2022-05-18 Linear Shaped Ltd Frame and linear shaped charge
TWI868528B (zh) * 2017-03-08 2025-01-01 日商武田藥品工業股份有限公司 Ｔｙｋ２抑制劑之生產方法
CN114269336A (zh) * 2019-04-30 2022-04-01 细胞基因公司 包含阿普斯特和tyk2抑制剂的联合疗法

Also Published As

Publication number Publication date
WO2020222773A1 (fr) 2020-11-05
AU2019443366A1 (en) 2021-12-02
JP2022537878A (ja) 2022-08-31
BR112021021826A8 (pt) 2022-06-21
KR20220002488A (ko) 2022-01-06
CN114206333A (zh) 2022-03-18
CA3138473A1 (fr) 2020-11-05
MX2021013317A (es) 2022-01-18
CN119454692A (zh) 2025-02-18
EP3962476A1 (fr) 2022-03-09
BR112021021826A2 (pt) 2022-01-04
SG11202112018YA (en) 2021-11-29
IL287670A (en) 2021-12-01
CO2021015614A2 (es) 2021-12-10
CL2021002847A1 (es) 2022-07-22
KR20220002489A (ko) 2022-01-06
CN114269336A (zh) 2022-04-01
BR112021021809A2 (pt) 2022-01-04
MX2021013318A (es) 2022-01-31
AU2020266143A1 (en) 2021-12-02
SG11202112043PA (en) 2021-11-29
IL287665A (en) 2022-07-01
EP3962475A1 (fr) 2022-03-09
WO2020223431A1 (fr) 2020-11-05
JP2022537877A (ja) 2022-08-31
JP7453251B2 (ja) 2024-03-19
CA3138686A1 (fr) 2020-11-05
CO2021015622A2 (es) 2022-02-28

Similar Documents

Publication Publication Date Title
IL282487A (en) Tyk2 inhibitors and uses thereof
EP3612181A4 (fr) Thérapies d'association avec des inhibiteurs d'ehmt2
IL286248A (en) Tyk2 inhibitors and uses thereof
GB201909190D0 (en) Therapeutic agents
GB201909191D0 (en) Therapeutic agents
PH12021551282A1 (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
GB201909194D0 (en) Therapeutic agents
IL276609A (en) Combined treatment with epilimod and glutamatergic factors
MA44890B1 (fr) Compositions comprenant des souches bactériennes
EP3906029A4 (fr) Inhibiteurs de l'interaction ménine-mll
MA46716A (fr) Polythérapie de thérapie cellulaire et d'inhibiteur de la microglie
IL284799A (en) Tyk2 inhibitors and uses thereof
MA52165A (fr) Inhibiteurs sélectifs de l'isoforme tgfbeta1 et utilisation associée
EP3773605A4 (fr) Dystrophines à régions charnières 1 et/ou 4 modifiées pour la thérapie de la dystrophinopathie
EP3609864A4 (fr) Inhibiteurs de hdac6 et agents d'imagerie
PL3972643T3 (pl) Antagoniści układu dopełniacza do stosowania w sposobach leczenia neuropatii paraproteinemicznych
EP4103186A4 (fr) Monothérapies et polythérapies avec des inhibiteurs de ulk1/2
GB201902277D0 (en) Therapeutic agents
IL287670A (en) Combined treatments including apremilaste and tyk2 inhibitors
MA47074A (fr) Formes pharmaceutiques comprenant des inhibiteurs de canaux de task-1 et task-3 et leur utilisation pour le traitement des troubles respiratoires
IL287704A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
GB201905520D0 (en) Compounds and their therapeutic use
EP3820382C0 (fr) Systèmes comprenant des guides d'alignement et des implants
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
GB201918541D0 (en) Therapeutic compounds and their use